Beren Therapeutics

Beren Therapeutics P.B.C. is a biopharmaceutical company, founded in 2020, that is currently operating in stealth mode. The company is focused on developing therapies using its cyclodextrin technology platform to address significant health challenges, particularly rare diseases.

The company's lead asset, BRN-002, is being developed to reverse atherosclerosis, the underlying cause of plaque in arteries. In November 2022, BRN-002 was awarded an Innovation Passport under the UK's Innovative Licensing and Access Pathway (ILAP). This designation is intended to accelerate the time to market for treatments addressing life-threatening or debilitating conditions, specifically for patients with Homozygous Familial Hypercholesterolemia (HoFH), a rare genetic disease. The company is also evaluating the safety and tolerability of BRN-002 administered intravenously in healthy adults.

Jason Camm serves as the CEO of the company, with Frank Langston as the Senior Vice President of Business Strategy. In May 2023, Beren Therapeutics entered into a strategic investment and innovation agreement with Roquette, a global leader in plant-based ingredients and pharmaceutical excipients. This partnership aims to expand the potential of Beren's cyclodextrin technologies and their medical applications, enhancing capabilities in manufacturing, safety protocols, and regulatory registration. The company has secured venture capital funding, including a seed round in 2020 for $30 million.

Keywords: cyclodextrin technology, biopharmaceutical, rare diseases, atherosclerosis, Homozygous Familial Hypercholesterolemia, BRN-002, clinical trials, drug development, stealth mode, venture capital-backed, cardiovascular disease, pharmaceutical manufacturing, regulatory affairs, ILAP, Innovation Passport, genetic disease treatment, drug discovery, life sciences, plant-based ingredients